患者对活性性结肠炎治疗和便微生物群移植的偏好
Deborah A Marshall1, Karen V MacDonald2, Dina Kao3
1Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Room 3C58, Health Research Innovation Centre, 3280 Hospital Drive NW, Calgary, AB T2N 4Z6, Canada.
Therapeutic advances in chronic disease
|March 28, 2024
概括
便微生物群移植 (FMT) 是对性结肠炎 (UC) 的有希望的治疗方法. 患者的偏好,特别是缓解和安全性,影响治疗选择,年轻,病情更严重的患者对FMT表现出更高的兴趣.
科学领域:
- 胃肠病学和肝病学
- 临床治疗学 临床治疗学
- 患者报告的结果
背景情况:
- 便微生物群移植 (FMT) 为活跃性结肠炎 (UC) 提供了一个新的治疗选择.
- 了解患者的偏好对于UC管理中的共享决策和以患者为中心的护理至关重要.
- 像FMT这样的新疗法需要对影响治疗接受度的患者特定因素进行彻底评估.
研究的目的:
- 量化患者对活性UC治疗的偏好,包括FMT和生物药物.
- 为了确定患者的特征与独特的偏好模式与UC疗法相关.
- 为新型UC治疗提供以患者为中心的护理策略提供信息.
主要方法:
- 一项采用离散选择实验 (DCE) 的横截面调查对加拿大UC成年人进行.
- 混合逻辑模型分析了DCE数据,以预测假设治疗场景的吸收.
- 隐性类型建模确定了患者偏好模式中的异质性.
主要成果:
- 几乎一半的参与者 (n=201) 表示愿意接受FMT.
- 影响选择的关键治疗属性是缓解的可能性和罕见的严重程度,未知的副作用.
- 口服囊/药丸是最喜欢的注射方法,其他方法均等.
- 更年轻的患有更严重UC的患者表现出更高的缓解效用和更大的FMT意愿.
结论:
- 患者偏好诱导方法可以识别易受FMT治疗的UC患者.
- 纳入患者偏好可以提高对UC治疗的满意度和坚持.
- 根据个体患者的异质性定制治疗策略,最大限度地提高治疗效果.
相关概念视频
Inflammatory Bowel Disease V: Surgical Management
145
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
145
Drugs for Treatment of Ulcerative Colitis in IBD
138
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
138
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
331
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
331
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
Drugs for Treatment of Constipation-Predominant IBS
162
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
162
Drugs for Treatment of Diarrhea-Predominant IBS
166
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
166


